ACP3
ENSG00000014257
Target class
Enzyme
Chromosome
3
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- ACP3
- Gene name
- Acid phosphatase 3
- Gene symbol
- ACP3
- Previous gene symbols
- ACPP
- Protein name
- Prostatic acid phosphatase (PAP) (EC 3.1.3.2) (5'-nucleotidase) (5'-NT) (EC 3.1.3.5) (Acid phosphatase 3) (Ecto-5'-nucleotidase) (Protein tyrosine phosphatase ACP3) (EC 3.1.3.48) (Thiamine monophosphatase) (TMPase) [Cleaved into: PAPf39]
- ACP-3
- PAP
- TM-PAP
- Gene biotype
- Protein coding
- Gene family
- Acid phosphatases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 18
- Highest tissue expression
- 1,281.35
- Tissue specificity (Gini)
- 0.962
- Tissue specificity (tau)
- 0.998
- KEGG gene identifiers
- hsa:55
- Reactome pathways
- R-HSA-6798695
- Protein interaction confidence
- 0.8549
- Protein interaction partners
- 10
- End position
- 132368302
- Start position
- 132317369
- Chromosome
- 3
- Strand
- Forward
- [Isoform 1]: Secreted .
- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane
- Single-pass type I membrane protein . Lysosome membrane
- Single-pass type I membrane protein . Nucleus . Cytoplasm, cytosol . Note=Appears to shuttle between the cell membrane and intracellular vesicles. Colocalizes with FLOT1 at cell membrane and in intracellular vesicles (PubMed:17638863). Colocalizes with LAMP2 on the lysosome membrane (PubMed:17897319). .
- PubMed 17638863
- PubMed 17897319
- PubMed 20498373
- Tissue specificity (tau)
- 0.9981
- Expression inequality (Gini)
- 0.961814
Expression in transcripts per million
- Prostate
- 1,281.35
- Esophagus - Mucosa
- 40.63
- Skin - Not Sun Exposed (Suprapubic)
- 16.51
- Skin - Sun Exposed (Lower leg)
- 16.46
- Vagina
- 9.84
Expression in transcripts per million
- Prostate1,281.35
- Esophagus - Mucosa40.63
- Skin - Not Sun Exposed (Suprapubic)16.51
- Skin - Sun Exposed (Lower leg)16.46
- Vagina9.84
- Kidney - Medulla6.85
- Minor Salivary Gland6.09
- Whole Blood5.23
- Kidney - Cortex3.84
- Lung2.41
- Adrenal Gland2.15
- Thyroid1.53
- Spleen1.5
- Colon - Transverse1.25
- Small Intestine - Terminal Ileum1.07
- Ovary1.05
- Stomach1.05
- Testis1.04
- Fallopian Tube0.91
- Pancreas0.82
- Cells - Cultured fibroblasts0.82
- Bladder0.8
- Adipose - Visceral (Omentum)0.63
- Breast - Mammary Tissue0.56
- Pituitary0.5
And 29 more, listed on the interactive page.
- GO:0046085
- GO:0051930
- GO:0060168
- GO:0005576
- GO:0005634
- GO:0005765
- GO:0005886
- GO:0035577
- GO:0070062
- GO:0003993
- GO:0004725
- GO:0005515
- GO:0008253
- GO:0016791
- GO:0042802
- GO:0042803
- GO:0052642
- GO:0060090
Related records
Trials (35)
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
- A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
- APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
- Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
- Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
- Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
- Docetaxel Followed by Provenge in Metastatic Prostate Cancer
- Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
- Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
- Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
- Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
- Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
- Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
- PROvenge Treatment and Early Cancer Treatment
- Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
- Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Drugs (1)
- Sipuleucel-T Prostatic acid phosphatase binding agent